Subcutaneous Romiplostim Increased Platelet Response in Children with ITP

Conference Correspondent 

The thrombopoietin‒receptor agonist romiplostim is approved for adults with chronic immune thrombocytopenia (ITP). Several phase 1/2 and 3 studies have been conducted to investigate the efficacy and safety of romiplostim in children with ITP; the current single-arm, open-label, global study evaluated subcutaneous romiplostim for ≤3 years in 204 children with ITP.

Eligible children must have had ITP for ≥6 months, received ≥1 prior ITP therapies, and had a platelet count ≤30 × 109/L or uncontrolled bleeding at screening. Treatment consisted of weekly subcutaneous dosing initiated at 1 μg/kg and titrated weekly in 1-μg/kg increments up to 10 μg/kg to target platelet counts of 50 to 200 × 109/L. The primary end point was the percentage of time with a platelet response in months 0 to 6, with response defined as a platelet count ≥50 × 109/L with no rescue medications in the past 4 weeks.

At the interim data cutoff, 203 patients received ≥1 doses. The median age of the study population was 10 years (range, 1-17 years), 51% were female. The median ITP duration was 1.8 years (range, 0.5-13.8 years); median baseline platelet count was 14 × 109/L. Patients had received a median of 2 (range, 1-7) prior ITP treatments, 34 (17%) patients were receiving concurrent ITP medications, and 10 (5%) patients had had prior splenectomy.

During the first 6 months, the median percentage of time with a platelet response was 50% (17%, 83%); the percentage of time ≥100 × 109/L was 17% (0%, 33%). During months 7-12, the median percentage of time with platelet response was 83% (50%, 100%). Over the course of the study, 88% of patients responded; the median percentage of time ≥100 × 109/L was 26% (5%, 48%). The median percentage of time with an increase in platelet counts ≥20 × 109/L above baseline was 74% (39%, 90%). From week 12 onward, median platelet counts were >50 × 109/L. There was no variation in platelet response and dose by age. Four patients had treatment-free periods and maintained platelet counts ≥50 × 109/L with no ITP medications (including romiplostim) for ≥24 weeks. Fifty-two (26%) patients received rescue medications; 3 patients had splenectomy on study.

Median treatment duration was 53 (range, 8-119) weeks for a total exposure time of 226 patient-years. Over the course of the study, patients received a median average weekly romiplostim dose of 6.9 (0.2-9.5) µg/kg; the median dose was 9 μg/kg at 1 year (n = 106) and 10 μg/kg at 2 years (n = 17). The majority (63%) of patients initiated self-administration because their platelet count was ≥50 × 109/L. The most common adverse events of any grade included epistaxis (32%), headache (31%), and viral upper respiratory tract infection (28%). Serious adverse events occurred in 41 (20%) patients, including epistaxis (5%), decreased platelet count (3%), and thrombocytopenia (1%); of these, 5 serious adverse events were deemed treatment-related: 2 headaches, 2 abdominal pain, and 1 each of presyncope and neutralizing antibodies. Overall, 64 (31%) patients discontinued treatment, mostly due to lack of efficacy (n = 38); 7 patients discontinued due to adverse events, including headaches (n = 2), abdominal pain (n = 1), dizziness (n = 1), interstitial lung disease (n = 1), mixed connective tissue disease (n = 1), neutralizing antibody (n = 1), lupus (n = 1), and vomiting (n = 1). Bleeding occurred in 62% of patients, with grade ≥3 bleeding noted in 17 (8%) patients, including epistaxis (4%), ecchymosis (1%), and contusion (1%); grade 4 bleeding events were reported in 2 patients.

There were 6 cases of neutralizing antibody to romiplostim (of 201 patients tested), but none to thrombopoietin; all discontinued due to antibodies, 5/6 had continued elevated platelet counts, and in 2/6 cases, antibodies were not found on retesting. Of 30 patients with baseline bone marrow biopsies (all with modified Bauermeister scores of grade 0 [no reticulin], 1 [fine fibers], or 2 [fine fiber network]), 27 had evaluable on-study biopsies after 1 year; 1 patient had an increase from grade 0 to 2. There was no follow-up biopsy for this patient; once at a steady dose of 10 μg/kg, most (10/16) of his platelet counts were ≥30 × 109/L. Four patients had an increase in 1 grade, 1 patient had a decrease in 2 grades, and 3 had a decrease in 1 grade. There were no findings of collagen or abnormalities.

These results demonstrated that the majority of children with ITP who received open-label romiplostim for ≥6 months achieved a platelet response, with median platelet counts >50 × 109/L from week 12 onward; no new safety signals were observed over 226 patient-years.

Grainger JD, et al. ASH 2017. Abstract 2334

Related Items


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: